Cell Lysis Market Size Is Projected to Reach US$ 5.2 Billion at a CAGR of 8.6% Till 2025 | Coherent Market Insights
Cell Lysis Market – Insights
Cell lysis refers to breaking down of the cell, generally by viral, enzymic or osmotic mechanisms that compromise its integrity. A fluid containing the contents of lysed cells is called lysate. Cell lysis is primarily used to break open cells to prevent shear forces that would denature or degrade sensitive DNA and proteins. Furthermore, cell lysis is also an important step to study protein-protein interaction, which supports growth of cell lysis market. Major players in the global cell lysis market are focusing on investing in R&D, to introduce advanced products used in cell lysis process. Furthermore, increasing demand for cell-based therapy for treatment purpose of cancer is also expected to augment growth of the cell lysis market. For instance, in 2017, US-based manufacturers Zymo Research Corp. and Bertin Technologies collaborated to develop real-time sample lysis step, which is carried out only in one minute.
For Any Queries Get Solutions With A FREE PDF Sample: https://www.coherentmarketinsights.com/insight/request-sample/741
The global cell lysis market was valued at US$ 2,715.1 billion in 2017 and is expected to witness a CAGR of 8.6 % over the forecast period (2017–2025).
Market Dynamics- Drivers
Robust research and development is expected to Drive Growth of the Global Cell Lysis Market
Increasing research and development activities in genomics and proteomics coupled with high prevalence of infectious disease and cancer are expected to drive growth of the global cell lysis market during the forecast period. For instance, According to 2012 EU Industrial R&D Investment Scoreboard, the pharmaceutical and biotechnology sectors represented 17.7% of business R&D expenditure in the world. Furthermore, in 2017, the U.S. Food and Drugs Administration (FDA) approved 2 CAR-T cell therapy for the treatment of patients up to age 25 years with B-cell precursor acute lymphoblastic leukemia and adult patients with certain types of large B-cell lymphoma. Therefore, development in cell-based therapy is expected to propel growth of the global cell lysis market over the forecast period.
Get Discount For First Time Buyers
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/741
Increase in Prevalence of Cancer Cases is also Driving Growth of the Cell Lysis Market
Growing prevalence of infectious disease and cancer worldwide, which leads to more utilization of cell samples for research and development of drugs is expected to fuel the global cell lysis market over the forecast period. For instance, According to GLOBOCAN 2012, an estimated 850,000 new cancer cases were diagnosed in Africa, while almost 600,000 deaths were attributed to malignant disease. The number of cancer cases is expected to rise to 1,056,000 by 2020. Furthermore, According to the World Health Organization (WHO), in 2012, around 3,319 deaths occurred due to the infectious and parasitic disease infection, in Sub Saharan Africa region and according to the same source, in 2014, Ebola accounted around 8,000 deaths in this region.
Moreover, increase in collaboration among government and market players is expected to propel the global cell lysis market growth during the forecast period. For instance, in September, 2015 African Academy of Sciences (AAS) and the New Partnership for Africa’s Development (NEPAD) Agency with got US$ 5.5 million in initial seed funding from the Bill & Melinda Gates Foundation, the Wellcome Trust and the UK Department for International Development launched Alliance for Accelerating Excellence in Africa (AESA). Furthermore, in 2016, Thermofisher scientific, Inc. partnered with Hamilton Bonaduz AG, to accelerate automation platform’s access to forensic customers. The automation platform includes AutoLys STAR 4×4 for sample lysis and DNA purification, which is the only hand-free automation solution for lysis and DNA extraction
Market Dynamics- Restraints
High cost associated with cell-based research, owing to high expenditure in research and development for CAR-T cell therapy is expected to restrain growth of the global cell lysis market over the forecast period. The U.S. FDA approved CAR T-Cell therapy is priced at US$ 475,000 for single infusion for pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia. Moreover, this cost does not include pre-infusion treatment cost, drug administration, hospitalization costs, and costs associated with adverse events and follow-up care
Global cell lysis market is segmented into six major regions- North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Among regions, North America holds the dominant position in the global cell lysis market. This is owing to increasing cell-based research due high demand for precision medicine in the region. In 2015, the Precision Medicine Initiative was launched in the U.S. to revolutionize the treatment of diseases, which include cancer and other chronic diseases, as precision medicine offers tailored treatment for an individual according to genetic makeup of the person. Moreover, Asia Pacific is expected to register significant growth in the global cell lysis market, owing to increasing number of research laboratories and pharmaceutical companies with increased expenditure on research and development. For instance, China’s expenditure on research and development has increased by 11.6% year-on-year to US$ 280 Bn in 2017.
Furthermore, according to the 13th five year plan for national science and technology talent development (2016-2020), China will increase its annual per capita spending on R&D to US$ 79,442 by 2020, up from US$ 58,787 in 2014.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/cell-lysis-market-to-surpass-us-52-billion-by-2025-846
Major companies operating in the global cell lysis market includes Thermo Fisher Scientific Inc., Merck & Co. Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., and Qsonica.About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire